ErSo - Trials on Mice have eradicated Metastatic Breast Cancer Cells - we need HUMAN trials now ...
Beating breast cancer Estrogen receptor–positive breast cancer is the most common type of breast cancer and, in its metastatic form, is currently incurable. In a new study, Boudreau et al. describe a compound, ErSO, that can activate the unfolded protein response, resulting in necrosis of human breast cancer cell lines in vitro. In vivo, this treatment induced complete regression of cell line and patient-derived orthotopic and metastatic breast cancer xenografts in mice. The authors showed that this treatment was well tolerated in mice, rats, and dogs and could provide a new avenue of intervention for this deadly disease. Abstract Metastatic estrogen receptor α (ERα)–positive breast cancer is presently incurable. Seeking to target these drug-resistant cancers, we report the discovery of a compound, called ErSO, that activates the anticipatory unfolded protein response (a-UPR) and induces rapid and selective necrosis of ERα-positive breast cancer cell lines in vitro. We then tested ErSO in vivo in several preclinical orthotopic and metastasis mouse models carrying different xenografts of human breast cancer lines or patient-derived breast tumors. In multiple orthotopic models, ErSO treatment given either orally or intraperitoneally for 14 to 21 days induced tumor regression without recurrence. In a cell line tail vein metastasis model, ErSO was also effective at inducing regression of most lung, bone, and liver metastases. ErSO treatment induced almost complete regression of brain metastases in mice carrying intracranial human breast cancer cell line xenografts. Tumors that did not undergo complete regression and regrew remained sensitive to retreatment with ErSO. ErSO was well tolerated in mice, rats, and dogs at doses above those needed for therapeutic responses and had little or no effect on normal ERα-expressing murine tissues. ErSO mediated its anticancer effects through activation of the a-UPR, suggesting that activation of a tumor protective pathway could induce tumor regression. https://news.illinois.edu/view/6367/339688859?fbclid=IwAR0h1IknctZG6-YwnsbeAm-4Q_Yi9piOYfUPc7z1ymYl-NIeZXH5W16zjUE#image-2 One lady actually wrote to one of the reseachers and he said to contact Bayer directly, as they bought the "rights" and as yet, they haven't scheduled clinical trials. I am sure that if controlling oestrogen was a major part of controlling Prostate or Testicular Cancer, they'd be RACING to get this to market ..... WE ALL NEED TO WRITE TO BAYER! Copy & Send this post to your Onc too!! Here is a Bayer contact the researcher gave: rose.talarico@bayer.com Hopefully, if LOTS OF PEOPLE from all around the world WRITE to Bayer - they may 'run with it' .... but the facts are, if something like this isn't profitable enough to them - it might get shelved! :(A new clinical Trial in Australia - Ember-4 (Endocrine/AI alternative) - has anyone heard of it?
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (These links show other BC Trials that are currently 'open' in Australia - but only the WA page mentions Ember-4 ... ) https://www.breastcancertrials.org.au/research/open-clinical-trials/ https://bcrc-wa.com.au/open-clinical-trials/ https://trials.cancervic.org.au/search/ (Put Breast Cancer in the search area) https://www.australianclinicaltrials.gov.au/anzctr-search-results?search_text=breast%2Bcancer&condition_category=all&condition_code=all&recruitment_status=Recruitingðics_approval=Yes Not sure if this will help anyone - it is a different form of AI they are 'testing' ... I found this info on the Ember-4 trial on one of the Facebook BC sites ..... (BTW, this is NOT written by me and does not relate to me in any way .. ) (SERDs are an important endocrine therapy used to treat ER-positive breast cancer. Parenteral SERD Fulvestrant has been approved and used in the treatment of metastatic ER-positive breast cancer for the last 2 decades.) From a Facebook BC Post: Is anyone else on the Ember-4 trial? I found out yesterday that I was selected in the trial to get Ilumestrant (a new SERD that replaces your AI) so that is quite exciting, but I ended up with horrible diarrhoea yesterday after taking my first dose, so hopefully that is not a side-effect that continues… Ilumestrant is a Selective Estrogen Receptor Degrader (SERD) that you take instead of taking an oestrogen blocker or aromatase inhibitor… it degrades the estrogen receptor sites in the cancer cells rather than blocking your oestrogen, so it allows your body to have some oestrogen and hopefully less joint aches and pains etc… An interesting thing about it is that you must fast for one hour before you take it, and for two hours after you take it. This will not be an issue for me, but I imagine it could be hard in some situations.Triple Negative Vaccine hopes to eliminate the disease - we need these trials in Australia NOW!
This is in the UK newspaper today - hopefully these trials will be in Australia SOON .... Maybe Ask your Onc about this ..... the sooner it starts here, the better. Triple Negative Breast cancer vaccine 'could eliminate disease by 2030' : 15 women who survived aggressive tumours are still in remission up to five years later after receiving experimental shot — now doctors believe a cure is in sight https://www.dailymail.co.uk/health/article-12140391/Breast-cancer-vaccine-eliminate-form-disease-seven-YEARS.html and another report from Dec 2022 https://www.dailymail.co.uk/health/article-11400715/Three-cancer-patients-cured-experimental-vaccine-100x-cheaper-rival-shots.htmlDo you have the BRCA1 Gene Mutation? Are you Interested in joining the BRCA-P trial?
This popped onto my FB feed .... thought it may interest those with the BRCA1 gene Game-Changing Research to Prevent Breast Cancer in Women with a BRCA1 Gene Mutation The BRCA-P clinical trial has the potential to become a game-changer in the way we manage breast cancer risk, by preventing the disease from ever developing in women with the BRCA1 gene mutation. Currently, many women with the BRCA1 gene mutation undertake life changing preventative measures for breast and ovarian cancer, including the surgical removal of their breasts and ovaries. The BRCA-P clinical trial hopes to offer these women a better prevention option. You can Participate in a world-first clinical trial to prevent breast cancer in women with the BRCA1 gene mutation. Are you Interested in joining the BRCA-P trial? Click on the link below: https://www.breastcancertrials.org.au/breastolution/
Targeted clinical trial for patients with lymphoedema related to breast cancer surgery
Hi members, The below clinical trial conducted by LeapCure may be of interest to some of you. If you have breast cancer surgery related lymphoedema following a dissection or biopsy procedure, you could be eligible to join a clinical trial that is enrolling nearby. Initial eligibility includes lymphoedema patients who have had surgery for their breast cancer at least 6 months ago and diagnosed with lymphoedema within the past 4 years. The following pre-screener will help you determine your suitability, match you to a nearby trial site, and enter you on to a list for the LeapCure team to give you a call back. To help you determine if you are eligible for the study, LeapCure, who are administering the recruitment of this study in Australia, have developed a survey found at the link below. By taking this survey, you are providing your consent (agreement) for LeapCure to collect and store your survey answers on an overseas server (large computer) that is compliant with the Health Insurance Portability and Accountability Act (USA). Here is the pre-screening link: https://research.leapcure.com/studies/bclymph?locale=en-AU&utm_source=BCNA&utm_medium=mixed&utm_campaign=060921Pv22&utm_cat=PAGNWAU&utm_study=bclymphClinical Trials Update
Hello members, Our BCNA Senior Policy Officer has provided the below information regarding clinical trials that may be of interest to our members. These are also being shared in our Health Professionals Network News and the Metastatic Advisory Group (I shall post in the mets private group re EMBRACE Phase II trial). Nivolumab neoadjuvant/adjuvant clinical trial The CA209-7FL neoadjuvant/adjuvant breast cancer trial continues to be open to recruitment, running in South Australia, New South Wales and Victoria for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. Bristol Myers Squibb will be implementing a digital advertising campaign expected to launch in October/November 2021. This will target both health professionals and patients. More information on the trial can be found here. EMBRACE Phase II Olaparib clinical trial EMBRACE is a Phase II clinical trial of the PARP inhibitor, Olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2. Patients with metastatic triple negative breast cancer (TNBC) or relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC) after first line/adjuvant therapy who have an eligible tumour molecular analysis result are suitable for the trial. There are 11 sites open in Australia in NSW, QLD, VIC, SA and WA. More information on the trial can be found here or by emailing embrace.study@sydney.edu.au We encourage members to talk with their treatment team in the first instance about any clinical trials.
Would you take part in a clinical trial?
So I've been approached by my oncologist to take part in a clinical trial of drug called Ribociclib- from my understanding it is one that has been used in the last few years to treat metsatic BC with good results. They are now trialling this with pre menopausal women like myself who have just finished treatment. Like all trials it entails many scans, appointments, time off work, blood work, having to deal with possible side effects.. all on top of looking after ny young family. And I just don't know if I can do it. I finally feel like I'm getting normality back in my life but I don't want to regret forgoing this opportunity (touch wood if I ever have a relapse..And then think how this trial could have helped me). This study is for 2 years. What would you do?
Immunotherapy trial on Atezolizumab
Hi everyone, I was just wondering if anyone on here is currently on the Atezolizumab clinical trial. I am about to start chemo and have also been offered the chance to participate in this clinical trial. The oncologist has given me all the information and side effects, but some of them sound really scary, although they're the uncommon ones. I was just hoping someone on here was already on this trial and could give me some insight into how they were going with it.
An already existing vaccine for breast cancer- at the Mayo Clinic?
Ok, when I read the article I thought "here we go, another miracle cancer cure that Google knows about yet somehow the Medical Oncology community dont k ow about".... Except that this is the Mayo Clinic, which is probably the most famous medical research institution in the world. Keith Knutson isnt a snake oil merchant. He is a very credible researcher. "But the fact is, Knutson said immunologists at Mayo already have two cancer vaccines against Triple Negative Breast Cancer and HER2 Positive Breast Cancer, respectively. " Is this real? Is there an actual vaccine? It is described as something to take after active treatment. I got in touch with the Mayo clinic and they sent me through a whole bunch of paperwork. https://www.forbes.com/sites/robinseatonjefferson/2019/10/11/mayo-breast-cancer-vaccine-could-be-available-in-less-than-a-decade/
NATALEE trial
New thread to discuss the NATALEE trial (double blinded study evaluating use of CDK4 inhibitor in hormone positive early BC) Feel free to post if you are likely to enrol/have already enrolled :) My Oncologists have said I am a good candidate and I would like to do my bit for the future treatment options, so am hopeful to get accepted. Supposedly coming to my hospital September ish. Already commenced in US.